About Erawat Pharma Limited
Data last updated:
Erawat Pharma Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the medical consumables and supplies segment of the healthcare sector. It was incorporated on 01 March 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U02423MP1993PLC007538. Its GSTIN is 23AAACE3757F1ZY (Madhya Pradesh).
The company has an authorised share capital of ₹6.95 Cr and a paid-up capital of ₹6.75 Cr. It was formerly known as Erawat Pharma Private Limited. It is led by directors including Hemchandra Jain (Managing Director) and Amit Jain (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 12C F A Scheme No. 94 Ring Road, Indore, Madhya Pradesh, India – 452010.
As per the financials filed for FY 2025, the company reported a revenue of ₹78.37 Cr, a growth of 14% compared to the previous year. For the same year it recorded a net loss of ₹2.51 Cr (net margin -3.2%) and EBITDA of ₹3.24 Cr (EBITDA margin 4.1%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 12% over five years.
The company has about 175 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Erawat Group and Erawat. As per MCA filings, the company has open charges of ₹50 Cr and satisfied charges of ₹29.78 Cr on record. Court records list 12 cases involving the company, including 10 filed by the company and 2 filed against it; 7 cases are pending. The company has 15 deals on record (11 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.16 Cr; the latest was in March 2022. Its 10 peer companies in the Healthcare industry (Medical Consumables) are compared by revenue, 5 larger and 5 smaller; the largest is Angstrom Biotech Private Limited with revenue of ₹86.9 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2020, listing 66 overdue payments to 45 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website erawat.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address12C F A Scheme No. 94 Ring Road, Indore, Madhya Pradesh, India – 452010
- IndustryHealthcare, Medical Consumables & Supplies
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Erawat Pharma Limited
The main business activity of Erawat Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Erawat Pharma Limited FY 2024 filings available
Erawat Pharma Limited reported revenue of ₹78.37 Cr (up 14% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Erawat Pharma Limited
Revenue has grown at a compounded annual rate (CAGR) of 12% over five years, including 14% growth in the latest year. EBITDA rose 30% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Erawat Pharma Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹3.24 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹2.51 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Erawat Pharma Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -3.2% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Erawat Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Erawat Pharma Limited
Erawat Pharma Limited is compared with the companies closest to it by revenue in the Healthcare industry (Medical Consumables). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Angstrom Biotech Private Limited | ₹86.9 Cr (FY 2022) | •••• | •••• | -2.0% | •••• | Vadodara, Gujarat, India |
| Sunil Healthcare Limited Listed | ₹84.76 Cr (FY 2025) | •••• | •••• | -11.0% | •••• | New Delhi, Delhi, India |
| Adeshwar Meditex Limited Listed | ₹83.97 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Mumbai, Maharashtra, India |
| Beacon Diagnostics Pvt Ltd | ₹82.21 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Navsari, Gujarat, India |
| R F B Latex Limited | ₹79.07 Cr (FY 2022) | •••• | •••• | -24.0% | •••• | New Delhi, Delhi, India |
| Erawat Pharma Limited this company | ₹78.37 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Indore, Madhya Pradesh, India |
| Medicare Hygiene Limited | ₹78.09 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Sanand, Gujarat, India |
| Amaryllis Healthcare Private Limited | ₹76.58 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Bangalore, Karnataka, India |
| Aegis Lifesciences Private Limited | ₹73.4 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | Ahmedabad, Gujarat, India |
| Miraclus Orthotech Private Limited | ₹73.1 Cr (FY 2025) | •••• | •••• | 35.0% | •••• | Kheda, Gujarat, India |
| Levram Lifesciences Private Limited | ₹72.95 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Erawat Pharma by revenue in the Healthcare industry (Medical Consumables), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Erawat Pharma Limited
Erawat Pharma Limited is audited by Mahesh Virendra & Co. for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Mahesh Virendra & Co. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Erawat Pharma Limited
Erawat Pharma has 7 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amit Jain Also directs: Swasti Kalyan Foundation, Anant Pharmacs Private Limited | Whole-Time Director | 01 Oct 2018 | 8 Years 0 Months | Current |
| Vasant Raj Solanki | Director | 16 Aug 1994 | 32 Years 1 Months | Current |
| Devindar Singh Sodhi Also directs: Dashmesh Sonail Healthcare Private Limited | Director | 30 Apr 1997 | 29 Years 5 Months | Current |
| Hemchandra Jain | Managing Director | 01 Mar 1993 | 33 Years 7 Months | Current |
| Abhijeet Jain Also directs: Swasti Kalyan Foundation, Anant Pharmacs Private Limited | Whole-Time Director | 01 Oct 2018 | 8 Years 0 Months | Current |
| Abhishek Jain Also directs: Swasti Kalyan Foundation, Jhanjhari Sons Leasing and Investment Pvt Ltd, Anant Formulations Private Limited and 1 more | Whole-Time Director | 11 Jul 2003 | 23 Years 3 Months | Current |
Ownership and Shareholding of Erawat Pharma Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Erawat Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Nov 2024 | Sidbi | ₹81.76 Lakh | Open |
| 26 Feb 2024 | Others | ₹89.08 Lakh | Open |
| 22 Nov 2023 | Sidbi | ₹1.28 Cr | Open |
| 13 Apr 2023 | Others | ₹8.24 Cr | Open |
| 21 Oct 2022 | Others | ₹6 Cr | Open |
Total charge records: 25 View all charges
Deals & Funding of Erawat Pharma Limited
Erawat Pharma Limited has 15 deals on record (11 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.16 Cr; the latest was in March 2022.
Deals on record (5 of 15)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2018 | Secondary share transfer | Undisclosed | Buyer: Hem Chandra Jain Huf, an individual Seller: Balaji Resources and Trading Limited , 3 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Hem Chandra Jain Huf, Zankar Leasing and Financing Pvt Ltd , 2 individuals |
| May 2008 | Secondary share transfer | Undisclosed | Buyer: Zankar Leasing and Financing Pvt Ltd , 3 individuals Seller: Erawat Engineering Pvt Ltd |
| Apr 2008 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Erawat Engineering Pvt Ltd |
| Feb 2008 | Secondary share transfer | Undisclosed | Buyer: Balaji Resources and Trading Limited , 3 individuals Seller: 4 individuals |
Full deal history
All 15 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Erawat Pharma Limited
Erawat Pharma Limited has 12 court cases on record: 10 filed by Erawat Pharma, 2 filed against it. 7 cases are pending and 5 are disposed. Status as checked between 28 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 12 | 2 | 7 |
Cases on record (5 of 12)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Interim or miscellaneous application | Filed against the company by Royal Palms (India) Private Limited | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Court case (Sum.Civ.Suit) | Filed against the company by Royal Palms (India) Private Limited | Pending |
| District court, Bhopal, Madhya Pradesh | Court case (MJC AV) | Filed by the company against Eurolife Healthcare Private Limited | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against Pureca Laboratories Private Limited | Pending |
| District court, Indore, Madhya Pradesh | Court case (SC NIA) | Filed by the company against Arcscare Bio Pharmaceuticals | Pending |
Full case history
All 12 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Erawat Pharma Limited
Erawat Pharma Limited has 4 MSME Form 1 returns on record between 2019 and 2020, listing 66 overdue payments to 45 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 45)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Anant Pharmac and Packaging System | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 4 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Erawat Pharma Limited
Erawat Pharma operates two associated brands: Erawat Group and Erawat. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures hard gelatin capsules and capsule manufacturing machines. | erawatgroup.com | |
| Manufacturing of empty hard capsules and HPMC capsules for pharmaceutical use in India. | erawat.com |
Employees and EPFO Compliance at Erawat Pharma Limited
Erawat Pharma Limited has a workforce of 175 employees as of Apr 05, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Erawat Pharma Limited
Erawat Pharma Limited has 14 board changes on record since 1993: 7 appointments and 7 cessations. The latest: Meena Jain ceased to be Additional Director on 26 Nov 2021.
52 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Erawat Pharma Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Erawat Pharma Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Erawat Pharma Limited
Erawat Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AAACE3757F1ZY | Madhya Pradesh | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Erawat Pharma Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Erawat Pharma Limited
Erawat Pharma is an active public limited company based in Indore, Madhya Pradesh, India. The company works in medical consumables and supplies, within the healthcare industry. It was incorporated on 01 March 1993 (33+ years old) and is registered under CIN U02423MP1993PLC007538.
Erawat Pharma reported revenue of ₹78.37 Cr for FY 2025 (up 14% YoY).
Erawat Pharma has 7 current directors:
- Hemchandra Jain - Managing Director
- Amit Jain - Whole-Time Director
- Abhijeet Jain - Whole-Time Director
- Abhishek Jain - Whole-Time Director
- Vasant Raj Solanki - Director
- Devindar Singh Sodhi - Director
- Meena Jain - Director
Erawat Pharma reported a net loss of ₹2.51 Cr (net margin -3.2%) and EBITDA of ₹3.24 Cr (EBITDA margin 4.1%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Erawat Pharma is 2% over three years and 12% over five years. In the latest year (FY 2025) revenue rose 14%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Erawat Pharma is 23AAACE3757F1ZY, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Erawat Pharma is U02423MP1993PLC007538. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Erawat Pharma has 12 court cases on record: 10 filed by the company and 2 filed against it. 7 are pending.
Erawat Pharma was incorporated on 01 March 1993, making it 33+ years old. It is registered with the Registrar of Companies, Gwalior.
Erawat Pharma has 15 deals on record (11 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.16 Cr; the latest was in March 2022.
The peers of Erawat Pharma by revenue are Angstrom Biotech Private Limited, Sunil Healthcare Limited, Adeshwar Meditex Limited, Beacon Diagnostics Pvt Ltd, R F B Latex Limited and 5 more, all in the Healthcare industry (Medical Consumables).
Meena Jain ceased to be Additional Director on 26 Nov 2021. Raj Kirtani ceased to be Director on 18 Oct 2021. Meena Jain was appointed as Director on 15 Jun 2021. Erawat Pharma has 14 board changes on record in total.